Delisting, Listing Rule Failure, or Listing Transfer

Business Context and Reporting Period

This Form 8-K was filed by Galecto, Inc., although the request metadata identifies Damora Therapeutics, Inc. The report concerns a Nasdaq listing deficiency received on September 27, 2023; it was signed on October 2, 2023. Galecto’s common stock trades on The Nasdaq Global Select Market under the symbol GLTO.

Financial and Operating Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.

Material Change Versus Prior Period

Nasdaq notified the company that its common stock had closed below the required minimum bid price of $1.00 per share for 30 consecutive business days. The deficiency letter did not immediately affect the stock’s listing or trading status.

Guidance, Outlook, Risks, and Unusual Items

  • The company has until March 25, 2024 to regain compliance.
  • Compliance generally requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
  • If compliance is not regained, the company may qualify for a second 180-calendar-day period by transferring to The Nasdaq Capital Market and meeting applicable initial listing requirements, subject to Nasdaq’s determination.
  • If the company fails to regain compliance by the end of the applicable period, its common stock may become subject to delisting. The company could appeal a delisting determination to a Nasdaq hearings panel.
  • Management stated that it may consider available actions, including a reverse stock split, but provided no assurance that compliance will be restored or that other Nasdaq listing requirements will be satisfied.

Important Facts to Verify

  • Confirm the registrant’s identity: the filing names Galecto, Inc., not Damora Therapeutics, Inc.
  • Monitor GLTO’s closing bid price and compliance with the $1.00 minimum bid-price requirement.
  • Verify whether the company regained compliance by March 25, 2024 or obtained a second compliance period.
  • Check for any subsequent reverse stock split, Nasdaq transfer, delisting notice, or appeal.
  • Review subsequent filings for financial condition, liquidity, and any additional listing-related risks not addressed in this 8-K.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.